Fundraising Overview - The company raised a total of RMB 1,483,482,000.00 through the issuance of 37,180,000 shares at a price of RMB 40.00 per share, with net proceeds after expenses amounting to RMB 1,378,838,926.21 [1][2] - As of June 30, 2025, the company has utilized RMB 1,102,682,065.36 of the raised funds, with RMB 103,363,523.27 used in the first half of 2025 [1][2] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure effective use and management of the raised funds [1][2] - A tripartite supervision agreement has been signed with banks to regulate the storage and use of the funds, ensuring compliance with the regulations [1][2] Fund Utilization - The funds have been allocated primarily to innovation drug research and development (R&D) projects, with RMB 653,160,459.45 used for this purpose [1][2] - The company has also utilized RMB 429,759,485.91 for working capital and has temporarily set aside RMB 300,000,000.00 for cash management [1][2] Cash Management - The company has engaged in cash management using temporarily idle funds, with a maximum limit of RMB 80,000,000.00 approved for investment in safe and liquid financial products [3][4] - As of June 30, 2025, the company has invested RMB 300,000,000.00 in structured deposits and large-denomination certificates of deposit [7][8] Project Adjustments - The company has made adjustments to its fundraising projects, including the addition of two sub-projects under the "New Drug R&D Project" and the termination of the base project, reallocating unused funds to support R&D efforts [10][11] - The company has also decided to terminate the clinical development of a specific drug candidate, SY-1530, based on market assessments and resource allocation [10][11] Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has disclosed the use and management of funds accurately and timely, with no violations reported [10][11]

证券代码：600547 证券简称：山东黄金 编号：临 2025-052 山东黄金矿业股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东黄金矿业股份有限公司（以下简称"公司"）严格按照《上市公司监管 指引第 2 号--上市公司募集资金管理和使用的监管要求（2022 年修订）》《上 海证券交易所上市公司自律监管指引第 1 号--规范运作》等相关规定存储和使用 募集资金，截至 2025 年 6 月 30 日，公司募集资金使用情况如下: 一、募集资金基本情况 （一）募集资金金额及到位时间 公司经中国证券监督管理委员会证监许可【2015】2540 号文《关于核准山 东黄金矿业股份有限公司向山东黄金集团有限公司等发行股份购买资产并募集 配套资金的批复》的核准，在发行股份购买资产的同时，向山东省国有资产投资 控股有限公司（以下简称"山东省国投"）、前海开源基金管理有限公司（以下 简称"前海开源")、山金金控资本管理有限公司（以下简称"山金金控"）、 烟台市金茂矿 ...

Fundraising Overview - The company raised a total of RMB 886.48 million through the issuance of 8,864,800 convertible bonds, with a net amount of RMB 870 million after deducting issuance costs [1] - As of December 31, 2024, a total of RMB 573.56 million has been directly invested in fundraising projects [1] - By June 30, 2025, the actual investment of fundraising funds amounted to RMB 622.50 million [2] Fund Management - The company has established a tripartite supervision agreement with banks to manage the raised funds, ensuring compliance with regulations [1] - As of June 30, 2025, the total balance of the fundraising funds in designated bank accounts was RMB 51.41 million [1] Fund Usage - The company did not use any idle fundraising funds to temporarily supplement working capital during the reporting period [2] - There were no changes in the fundraising investment projects during the reporting period [2] - The company has not used any surplus funds for permanent working capital supplementation or to repay bank loans [3] Cash Management - The company has approved the use of up to RMB 400 million of idle fundraising funds and RMB 600 million of self-owned funds for cash management, with a rolling investment period of 12 months [3] - The company has invested in various financial products with expected annualized returns ranging from 2.09% to 2.19% [3]

Core Points - The report details the fundraising and usage status of Hubei Huqiang Technology Co., Ltd. for the first half of 2025, ensuring compliance with regulatory requirements [1][5] - The total amount raised through the public offering was approximately RMB 3.02 billion, with a net amount of RMB 2.81 billion after deducting issuance costs [1][3] - As of June 30, 2025, the company has utilized RMB 1.51 billion of the raised funds, with a remaining balance of RMB 1.44 billion [1][4] Fundraising Overview - The company issued 86,206,200 shares at a price of RMB 35.09 per share, resulting in total fundraising of RMB 3,024,975,558.00 [1] - The funds were received on December 1, 2021, and have been audited by Da Xin Accounting Firm [1][2] Fund Usage - Cumulative usage of the raised funds as of June 30, 2025, was RMB 1,507,281,356.38, with RMB 264,318,264.54 used in the current year [1][4] - The remaining balance in the special account for the raised funds was RMB 1,435,171,906.68 [1][4] Fund Management - The company has established a management system for the raised funds, ensuring they are stored in a special account and used according to regulations [1][3] - A tripartite supervision agreement was signed with banks and the sponsor, ensuring compliance with fund management [1][3] Cash Management - The company has utilized part of the temporarily idle raised funds for cash management, with an amount of RMB 1,287,623,759.08 invested in structured deposits and other financial products [3][4] - The maximum amount for cash management is capped at RMB 2 billion, with a focus on low-risk financial products [3][4] Project Adjustments - The company has adjusted the implementation plans for several fundraising projects, including reducing the investment for the "New Nuclear Biological Emergency Rescue Protective Equipment Industrialization Production Base Project" from RMB 772 million to RMB 387.54 million [5][6] - New projects have been added, such as the "New Drug Delivery Device and Packaging Materials R&D and Industrialization Project," with a total investment of RMB 397.53 million [5][6] Compliance and Reporting - The company has confirmed that there are no discrepancies between the disclosed fundraising usage and the actual usage, ensuring timely and accurate reporting [5][6] - There are no instances of using raised funds for non-compliant purposes or for repaying bank loans [5][6]

Fundraising Overview - The company raised a total of RMB 6,103,279,992.42 through a non-public offering of 381,693,558 shares at a price of RMB 15.99 per share, with a net amount of RMB 6,020,040,632.51 after deducting issuance costs [1] - As of June 30, 2025, the cumulative use of raised funds amounted to RMB 4,808,765,200, with RMB 4,512,690 allocated in the 2025 fiscal year [1] - The remaining balance of unused funds is RMB 1,550,849,557.38, which includes interest income of RMB 352,225,400 [1] Fund Management - The company has established a fundraising management method in compliance with relevant laws and regulations to ensure proper management and usage of the funds [1] - The company signed tripartite supervision agreements with banks and independent financial advisors to manage the funds securely [1] Fund Usage - The company has not used idle funds to temporarily supplement working capital during the reporting period [2] - The company has approved the use of up to RMB 1,431,000,000 of temporarily idle funds for cash management, with a rolling usage within a 12-month period [2] - As of June 30, 2025, the company maintained a balance of RMB 1,431,000,000 in structured deposits [2] Investment Projects - The company has not reported any early investments or replacements for fundraising projects during the reporting period [2] - There are no instances of using excess funds for ongoing or new projects, including asset acquisitions [5] Financial Products - The company has engaged in cash management through structured deposits, which are considered low-risk and provide liquidity [5] - The total income from financial products that have matured is RMB 20,858,500, with no overdue or restricted funds reported [5]

证券代码：600406 证券简称：国电南瑞 公告编号：临 2025-050 经国电南瑞科技股份有限公司（以下简称"国电南瑞"、"公司"）监事会 于 2025 年 8 月 15 日以会议通知召集，公司第九届监事会第三次会议于 2025 年 席战广生先生主持。会议符合《公司法》和《公司章程》的有关规定，会议合法 有效。经会议审议，形成如下决议： 一、会议以 3 票同意，0 票反对，0 票弃权，审议通过关于 2025 年半年度募 集资金存放与使用情况专项报告的议案。 二、会议以 3 票同意，0 票反对，0 票弃权，审议通过关于使用部分闲置募 集资金进行现金管理及暂时补充流动资金的议案。 监事会根据募集资金相关规定，发表意见如下： 国电南瑞科技股份有限公司 第九届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 五、会议以 3 票同意，0 票反对，0 票弃权，审议通过关于 2025 年半年度报 告及摘要的议案。 监事会根据半年度报告相关规定，审核意见如下： 规定的要求； 半年度的经营管理和财务状况等事项； ...

Meeting Overview - The fourth supervisory board's ninth meeting of Guangdong Huate Gas Co., Ltd. was held on August 26, 2025, via in-person and communication methods [1] - The meeting was notified to all supervisors on August 15, 2025, via email [1] Resolutions Passed Half-Year Report - The supervisory board approved the proposal regarding the 2025 half-year report, affirming that it was prepared in accordance with relevant laws and internal regulations, accurately reflecting the company's financial status and operational results [1][2] - No violations of confidentiality were found during the preparation and review of the half-year report [1] Fund Management Report - The supervisory board also approved the special report on the management and actual use of raised funds for the first half of 2025, confirming it complies with all major legal and regulatory requirements [2] - The report accurately reflects the actual storage and usage of raised funds, with no evidence of misappropriation or harm to shareholder interests [2]

Core Viewpoint - Jiangsu Guotai's 1.5 billion yuan securities investment plan was abruptly terminated within two days due to market skepticism, with the company stating a focus on its core business and prudent investment strategies [3][6]. Group 1: Securities Investment Plan - The company announced a plan to use up to 1.5 billion yuan of idle funds for securities investment, which was approved unanimously by the board [3]. - The plan faced criticism for diverting from the company's main operations, leading to its quick termination [3][6]. - Prior investments included shares in companies like Shenda Co. and Tianji Co., with significant losses reported in some cases [4][5]. Group 2: Financial Management - In the first half of 2025, Jiangsu Guotai spent 202.42 billion yuan on bank wealth management products, exceeding its operating cash outflow of 201.65 billion yuan [6]. - The company plans to raise 2.5 billion yuan through a bond issuance to repay bank loans, despite having a cash balance of 125.71 billion yuan at the end of the reporting period [7]. Group 3: Project Termination - The company announced the termination of a 1.5 billion yuan lithium battery electrolyte project due to delays in land delivery and market conditions leading to overcapacity [8][9]. - The project was initially expected to generate significant revenue and profit, but the anticipated returns have diminished [8]. Group 4: Regulatory Compliance - New regulations emphasize that raised funds should be used specifically for ongoing projects and not for repaying loans or supplementing working capital [10].

Summary of Key Points Core Viewpoint The report provides a detailed account of the fundraising activities and the management of the raised funds by Zhonggang Luonai Technology Co., Ltd. It outlines the total amount raised, the usage of the funds, and the remaining balance as of June 30, 2025, while also addressing the management protocols in place to ensure compliance with regulatory requirements. Fundraising Overview - The company raised a total of RMB 1,138,500,000 through the issuance of 22.5 million shares at RMB 5.06 per share, with a net amount of RMB 1,072,459,905.66 after deducting underwriting fees and other expenses [1]. - As of June 30, 2025, the remaining balance of the raised funds is RMB 764,283,999.71, which includes RMB 214,283,999.71 in current accounts and RMB 550,000,000 in bank large deposits [1][2]. Fund Usage and Management - The company has utilized RMB 329,485,476.98 of the raised funds for investment projects, with additional amounts used to replace self-funded expenses [1][2]. - The company has established a dedicated fund management system in compliance with relevant laws and regulations, ensuring that funds are stored in special accounts and managed according to a three-party supervision agreement [1][3]. Project Status and Adjustments - Four investment projects have been postponed, including the annual production of 90,000 tons of new refractory materials and the new materials research center [3][6]. - The company has terminated two sub-projects related to the annual production of 30,000 tons of high-temperature magnesium-based new refractory materials and 20,000 tons of high-temperature aluminum-based new refractory materials due to changes in market conditions [3][4]. Compliance and Reporting - The company has adhered to the regulatory requirements for fundraising and has effectively disclosed information regarding the management and usage of the raised funds, with no violations reported [3][6].

Fundraising Overview - The company raised a total of RMB 625.665 million by issuing 79.5 million shares at a price of RMB 7.87 per share, with a net amount of RMB 561.123 million after deducting issuance costs of RMB 64.542 million [1] - As of June 30, 2025, the company has invested RMB 395.608 million in fundraising projects, with a remaining balance of RMB 22.296 million [1][2] Fund Management - The company has established a fundraising management system in compliance with relevant regulations to ensure proper management and usage of the raised funds [1] - A tripartite supervision agreement has been signed with the relevant financial institutions to ensure the safety and proper management of the funds [1] Fund Usage - There were no early investments or replacements for fundraising projects during the reporting period [2] - The company has not used idle funds for temporary working capital or to repay bank loans [2][3] - As of June 30, 2025, the company has utilized idle funds for cash management, with a balance of RMB 100 million allocated for this purpose [2][6] Project Status - The company has not changed the use of fundraising projects during the reporting period [3] - There are no issues regarding the usage and disclosure of fundraising funds, and the company has complied with all relevant laws and regulations [3]